Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- cyclophosphamide
- Nipent (pentostatin)
Interactions between your drugs
cycloPHOSphamide pentostatin
Applies to: cyclophosphamide, Nipent (pentostatin)
MONITOR: Coadministration of pentostatin with cyclophosphamide may enhance the cardiotoxic effects of cyclophosphamide. The mechanism of this interaction has not been delineated. Two cases of fatal cardiovascular collapse have been reported following administration of intravenous pentostatin with high-dose oral cyclophosphamide.
MANAGEMENT: Patients receiving pentostatin and cyclophosphamide should be monitored for development of signs and symptoms of cardiotoxicity including, but not limited to respiratory distress, pulmonary edema, hypotension, hypothermia, and confusion. Some authorities recommend avoiding the use of intravenous pentostatin with high-dose oral cyclophosphamide.
References (4)
- (2001) "Product Information. Cytoxan (cyclophosphamide)." Bristol-Myers Squibb
- (2001) "Product Information. Nipent (pentostatin)." Hospira Inc
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
Drug and food/lifestyle interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Benlysta
Benlysta is used to treat active systemic lupus erythematosus (SLE) and active lupus nephritis. It ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Saphnelo
Saphnelo is used for moderate to severe SLE (lupus) for adults who are also receiving other lupus ...
Tavneos
Tavneos (avacopan) is a C5a receptor antagonist used for severe active ANCA-associated vasculitis ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.